Discovery could also benefit regenerative medicine therapies
MINNEAPOLIS (June 6, 2017) — A research study led by University of Minnesota engineers gives new insight into how cancer cells move based on their ability to sense their environment. The discovery could have a major impact on therapies to prevent the spread of cancer.
The research is published in Nature Communications, a leading research journal.
MINNEAPOLIS and ST. PAUL, Minn., May 17, 2017 /PRNewswire/ -- The University of Minnesota Medical School is proud to announce Clark Chen, MD, Ph.D., as the Lyle French Chair in Neurosurgery and the Head of the University of Minnesota Medical School Department of Neurosurgery.
MINNEAPOLIS/ST. PAUL (February 28, 2017) – Survivors of childhood cancers have fewer secondary cancers, according to new research from the Masonic Cancer Center, University of Minnesota and St. Jude Children’s Research Hospital. Compared with those diagnosed in the 1970s, patients diagnosed after 1990 are experiencing better outcomes. Researchers believe the difference comes from a reduction in exposure to therapeutic radiation.
MINNEAPOLIS/ST.PAUL (February 13, 2017) – A breakthrough trial at the University of Minnesota testing a new UMN-developed drug resulted in improved survival rates for dogs diagnosed with a cancer called hemangiosarcoma (HSA). The results were published today in the journal Molecular Cancer Therapeutics.
MINNEAPOLIS/ST. PAUL (December 23, 2016) – The Big Ten Cancer Research Consortium (Big Ten CRC) elected Robert Kratzke, M.D., lung cancer researcher, Masonic Cancer Center, University of Minnesota and associate professor in the University of Minnesota Medical School's Department of Medicine, as its inaugural Steering Committee Chair. Kratzke will lead the initiative to transform cancer research through collaboration across Big Ten universities.
MINNEAPOLIS/ST. PAUL (December 19, 2016) – Unprecedented images of cancer genome-mutating enzymes acting on DNA provide vital clues into how the enzymes work to promote tumor evolution and drive poor disease outcomes. These images, revealed by University of Minnesota researchers, provide the first ever high-resolution pictures of molecular complexes formed between DNA and the human APOBEC3A and APOBEC3B enzymes.
A new study in JAMA Oncology finds that antibodies to human papillomavirus detectable in blood serum are reliable indicators of five-year head and neck cancer survival
MINNEAPOLIS/ST. PAUL (November 30, 2016) – Frequent genetic rearrangements in the androgen receptor could be limiting treatment options for prostate cancer patients, according to new research out of the University of Minnesota. Currently, the main treatment for prostate cancer inhibits androgen receptor activity. However, the new paper identified frequent rearrangements in the metastases of prostate cancer, allowing cancer cells to accumulate a variety of receptor forms and increasing resistance to treatments.
Giving to cancer
Invested and focused